Skip to main content

Advertisement

SpringerLink
Log in

Adverse Effects of Thyroid Hormones

  • Review Article
  • Adverse Effects
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The adverse health effects of thyrotoxicosis have been carefully documented and most practitioners are familiar with the clinical consequences for the patient. Until recently, many patients experienced the adverse effects of excessive thyroxine dosages, which can now be avoided by the application of highly sensitive immunometric assays for monitoring serum thyrotrophin (thyroid-stimulating hormone; TSH) levels. However, sensitive monitoring of serum thyrotrophin levels has led to the frequent recognition of biochemical subclinical hyperthyroidism (isolated suppression of thyrotrophin). Because of the increased recognition of this condition, the adverse effects of thyroxine therapy can be divided into those associated with subclinical hyperthyroidism and those associated with the euthyroid state.

Investigation of the potential clinical consequences of thyrotrophin-suppressing dosages of thyroxine has dominated studies over the last decade, with less attention being given to euthyroid patients. It appears that the adverse effects of thyroxine are considerably more common when serum thyrotrophin has been suppressed. They are usually manifested in older patients as increased bone mineral loss in postmenopausal women and as cardiac effects in patients with intrinsic heart disease. These patients may have subtle behavioural alterations and other clinically silent organ effects that occur infrequently.

Children who are euthyroid while taking thyroxine occasionally develop pseudotumour cerebri shortly after starting hormone replacement for hypothyroidism. Otherwise, thyroxine dosages that render patients euthyroid, as evidenced by thyrotrophin values that are within the normal range, rarely cause adverse effects. Thus, avoidance of dosages that cause thyrotrophin suppression, when not clinically indicated, is the primary approach to the management of these adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zoeller J. The top 200 drugs. Am Druggist 1997; 214: 32–7

    Google Scholar 

  2. Roti E, Minelli R, Gardini E, et al. The use and misuse of thyroid hormone. Endocr Rev 1993; 14: 401–23

    PubMed  CAS  Google Scholar 

  3. Ross DS. Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy. Mayo Clin Proc 1988; 63: 1223–9

    PubMed  CAS  Google Scholar 

  4. Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf 1996; 15: 53–63

    Article  PubMed  CAS  Google Scholar 

  5. Klein I, Levey GS. The cardiovascular system in thyrotoxicosis. In: Braverman LE, Utiger RD, editors. The thyroid. Philadelphia: Lippincott-Raven, 1996: 607–15

    Google Scholar 

  6. Klein I, Ojamaa K. The cardiovascular system in hypothyroidism. In: Braverman LE, Utiger RD, editors. The thyroid. Philadelphia: Lippincott-Raven, 1996: 799–804

    Google Scholar 

  7. Klein I, Ojamaa K. Cardiovascular manifestations of endocrine disease. J Clin Endocrinol Metab 1992; 75: 339–42

    Article  PubMed  CAS  Google Scholar 

  8. Polikar R, Feld GK, Dittrich HC, et al. Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. J Am Coll Cardiol 1989; 14: 999–1002

    Article  PubMed  CAS  Google Scholar 

  9. Toft AD. Thyroxine therapy. N Engl J Med 1994; 331: 174–80

    Article  PubMed  CAS  Google Scholar 

  10. Bell GM, Sawers JSA, Forfar JC, et al. The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. Clin Endocrinol 1983; 18: 511–6

    Article  CAS  Google Scholar 

  11. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77: 334–8

    Article  PubMed  CAS  Google Scholar 

  12. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab 1995; 80: 2222–6

    Article  PubMed  CAS  Google Scholar 

  13. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249–52

    Article  PubMed  CAS  Google Scholar 

  14. Ching GW, Franklyn JA, Stallard TJ, et al. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart 1996; 75: 363–8

    Article  PubMed  CAS  Google Scholar 

  15. Radetti G, Paganini C, Crepaz R, et al. Cardiovascular effects of long-term thyroxine therapy for Hashimoto’s thyroiditis in children and adolescents. Eur J Endocrinol 1995; 132: 688–92

    Article  PubMed  CAS  Google Scholar 

  16. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 1997; 82: 2592–5

    Article  PubMed  CAS  Google Scholar 

  17. Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol 1992; 37: 500–3

    Article  CAS  Google Scholar 

  18. Baran DT. The skeletal system in thyrotoxicosis. In: Braverman LE, Utiger RD, editors. The thyroid. Philadelphia: Lippincott-Raven, 1996: 678–86

    Google Scholar 

  19. Faber J, Galløe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130: 350–6

    Article  PubMed  CAS  Google Scholar 

  20. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81: 4278–89

    Article  PubMed  CAS  Google Scholar 

  21. Ross DS, Neer RM, Ridgway EC, et al. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with thyroxine. Am J Med 1987; 82: 1167–70

    Article  PubMed  CAS  Google Scholar 

  22. Paul TL, Kerrigan J, Kelly AM, et al. Long-term thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259: 3137–41

    Article  PubMed  CAS  Google Scholar 

  23. Greenspan SL, Greenspan FS, Resnick NM, et al. Skeletal integrity in premenopausal and postmenopausal women receiving long-term thyroxine therapy. Am J Med 1991; 91: 5–14

    Article  PubMed  CAS  Google Scholar 

  24. Adlin EV, Maurer AH, Marks AD, et al. Bone mineral density in postmenopausal women treated with thyroxine. Am J Med 1991; 90: 360–6

    Article  PubMed  CAS  Google Scholar 

  25. Franklyn JA, Sheppard MC. Thyroxine replacement treatment and osteoporosis. BMJ 1990; 300: 693–4

    Article  PubMed  CAS  Google Scholar 

  26. Lehmke J, Bogner U, Felsenberg D, et al. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol 1992; 36: 511–7

    Article  CAS  Google Scholar 

  27. Florkowski CM, Brownlie BE, Elliot JR, et al. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. N Z Med J 1993; 106: 443–4

    PubMed  CAS  Google Scholar 

  28. Marcocci C, Golia F, Bruno-Bossio G, et al. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994; 78: 818–23

    Article  PubMed  CAS  Google Scholar 

  29. De Rosa G, Testa A, Maussier, et al. A slightly suppressive dose of thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre. Horm Metab Res 1995; 27: 503–7

    Article  PubMed  Google Scholar 

  30. Langdahl BL, Loft AG, Eriksen EF, et al. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. Eur J Endocrinol 1996; 134: 702–9

    Article  PubMed  CAS  Google Scholar 

  31. Stall GM, Harris S, Sokoll LJ, et al. Ann Intern Med 1990; 113: 265–9

    PubMed  CAS  Google Scholar 

  32. Kung AW, Lorentz T, Tarn SC. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol 1993; 39: 535–40

    Article  CAS  Google Scholar 

  33. Affinito P, Sorrentino C, Farace MJ, et al. Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism. Acta Obstet Gynecol Scand 1996; 75: 843–8

    Article  PubMed  CAS  Google Scholar 

  34. Görres G, Kaim A, Otte A, et al. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur J Nucl Med 1996; 23: 690–2

    Article  PubMed  Google Scholar 

  35. Frevert EU, Biester A, Muller MJ, et al. Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. Eur J Endocrinol 1994; 131: 145–9

    Article  PubMed  CAS  Google Scholar 

  36. Guo C-Y, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 1997; 46: 301–7

    Article  CAS  Google Scholar 

  37. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly men. Arch Intern Med 1995; 155: 2005–7

    Article  PubMed  CAS  Google Scholar 

  38. Toh SH, Brown PH. Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J Bone Miner Res 1990; 5: 463–7

    Article  PubMed  CAS  Google Scholar 

  39. Marcocci C, Golia F, Vignali E, et al. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 1997; 12: 72–7

    Article  PubMed  CAS  Google Scholar 

  40. Cummings SR, Nevitt MC, Browser WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767–73

    Article  PubMed  CAS  Google Scholar 

  41. Wejda B, Hintze G, Katschinski B, et al. Hip fractures and the thyroid: a case control study. J Intern Med 1995; 237: 241–7

    Article  PubMed  CAS  Google Scholar 

  42. Solomon BL, Wartofsky L, Burman KD. Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993; 3: 17–23

    Article  PubMed  CAS  Google Scholar 

  43. Orwoll ES, Bauer DC, Vogt TM, et al. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1996; 124: 187–96

    PubMed  CAS  Google Scholar 

  44. Franklyn JA, Betteridge J, Holder R, et al. Effect of estrogen replacement therapy upon bone mineral density in thyroxinetreated postmenopausal women with a past history of thyrotoxicosis. Thyroid 1995; 5: 359–63

    Article  PubMed  CAS  Google Scholar 

  45. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women: effects of estrogen. JAMA 1994; 271: 1245–9

    Article  PubMed  CAS  Google Scholar 

  46. Van Dop C, Conte FA, Koch TK, et al. Pseudotumor cerebri associated with initiation of levothyroxine therapy for juvenile hypothyroidism. N Engl J Med 1983; 308: 1076–80

    Article  PubMed  Google Scholar 

  47. Huseman CA, Torkelson RD. Pseudotumor cerebri following treatment of hypothalamic and primary hypothyroidism. Am J Dis Child 1984; 138: 927–31

    PubMed  CAS  Google Scholar 

  48. Rohn R. Pseudotumor cerebri following treatment of hypothyroidism [letter]. Am J Dis Child 1985; 139: 752

    PubMed  CAS  Google Scholar 

  49. Panza N, De Rosa M, Lombardi G, et al. Pseudotumor cerebri and thyroid-replacement therapy in patients affected by differentiated thyroid carcinoma. J Endocrinol Invest 1985; 8: 357–8

    PubMed  CAS  Google Scholar 

  50. Rovet JF, Daneman D, Bailey JD. Psychologic and psychoeducational consequences of thyroxine therapy for juvenile acquired hypothyroidism. J Pediatr 1993; 122: 543–9

    Article  PubMed  CAS  Google Scholar 

  51. Gow SM, Caldwell G, Toft AD, et al. Relationship between pituitary and other target organ responsiveness in hypothyroid patients receiving thyroxine replacement. J Clin Endocrinol Metab 1987; 64: 364–70

    Article  PubMed  CAS  Google Scholar 

  52. Al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 1997; 82: 1118–25

    Article  PubMed  CAS  Google Scholar 

  53. Lahat N, Sheinfeld M, Baron E, et al. Thyroxine-induced leukopenia in a patient with Hashimoto’s disease: involvement of suppressor-cytotoxic T cells. J Clin Endocrinol Metab 1985; 61: 980–2

    Article  PubMed  CAS  Google Scholar 

  54. Shibata H, Hayakawa H, Hirukawa M, et al. Hypersensitivity caused by synthetic thyroid hormones in a hypothyroid patient with Hashimoto’s thyroiditis. Arch Intern Med 1986; 146: 1624–5

    Article  PubMed  CAS  Google Scholar 

  55. Butland RJ, Pang JA, Geddes DM. Thyroxine and dyspnoea in emphysema. Br J Dis Chest 1981; 75: 96–8

    Article  PubMed  CAS  Google Scholar 

  56. Costigan DC, Freedman MH, Ehrlich RM. Potentiation of oral anticoagulant effect by thyroxine. Clin Pediatr 1984; 23: 172–4

    Article  CAS  Google Scholar 

  57. Oppenheimer JH, Braverman LE, Toft A, et al. A therapeutic controversy. Thyroid hormone treatment: when and what? J Clin Endocrinol Metab 1995; 80: 2873–83

    Article  PubMed  CAS  Google Scholar 

  58. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993; 119: 492–502

    PubMed  CAS  Google Scholar 

  59. Stockgist JR. Serum thyrotropin and thyroid hormone measurements and assessment of thyroid hormone transport. In: Braverman LE, Utiger RD, editors. The thyroid. Philadelphia: Lippincott-Raven, 1996: 377–96

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Diabetes, Room 715 MRB II, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232-6303, USA

    John B. Williams

Authors
  1. John B. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John B. Williams.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, J.B. Adverse Effects of Thyroid Hormones. Drugs & Aging 11, 460–469 (1997). https://doi.org/10.2165/00002512-199711060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199711060-00005

Keywords

Search

Navigation